ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ...

BioTime, Inc.BTX was a big mover last session, as the company saw its shares rise above 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.

BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced ™Portal Offering Additional ™ Human Progenitor Cells Including Those for Diabetes Research BioTime, Inc. (NYSE MKT: BTX) and ...

BioTime, Inc. BTX was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal ...

ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical ...

Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset Contribution Agreement (the "Agreement") with Geron Corporation ...

On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...

Adi Mohanty became Co-Chief Executive Officer of BioTime, Inc. in October 2015. He is also a Director of BioTime company OncoCyte Corporation and BioTime affiliate Asterias Biotherapeutics. Mr.